Gene Expression Profiling in Lungs of Chronic Asthmatic Mice Treated with Galectin-3 : Downregulation of Inflammatory and Regulatory Genes

Abstract EN

Background.

Asthma is a disorder characterized by a predominance of Th2 cells and eosinophilic inflammation.

Suppressors of cytokine signaling (SOCS) proteins act as negative regulators of cytokine signaling.

In particular, SOCS1 and SOCS3 play an important role in immune response by controlling the balance between Th1 and Th2 cells.

In a previous study, we demonstrated that treatment of chronic asthmatic mice with gene therapy using plasmid encoding galectin-3 (Gal-3) led to an improvement in Th2 allergic inflammation.

Methods.

Using a microarray approach, this study endeavored to evaluate the changes produced by therapeutic Gal-3 delivered by gene therapy in a well-characterized mouse model of chronic airway inflammation.

Results were confirmed by real-time RT-PCR, Western blot and immunohistochemical analysis.

Results.

We identify a set of genes involved in different pathways whose expression is coordinately decreased/increased in mice treated with Gal-3 gene therapy.

We report a correlation between Gal-3 treatment and inhibition of SOCS1 and SOCS3 expression in lungs.

Conclusion.

These results suggest that negative regulation of SOCS1 and 3 following Gal-3 treatment could be a valuable therapeutic approach in allergic disease.